Pioneering Discussions at IPC’s Conclave on Indian Pharmacopoeia 2026

The Indian Pharmacopoeia Commission (IPC) recently hosted an influential Scientific Conclave and Interactive Session at the National Institute of Pharmaceutical Education and Research (NIPER) in Hyderabad. This event, organized in collaboration with NIPER, Central Drugs Standard Control Organization (CDSCO), and the Indian Drug Manufacturers' Association (IDMA) Telangana Chapter, was centered on the theme 'Significance of Indian Pharmacopoeia Reference Standards and Impurity Standards in Ensuring Pharmaceutical Quality.'

Key players from the pharmaceutical, clinical, regulatory, and industrial sectors convened to discuss the clinical implications of pharmacopoeial impurities and their impact on patient safety. IPC's role in promoting the quality, safety, and rational use of medicines was underscored, with the conclave focusing on Indian Pharmacopoeia Reference Substances (IPRS) and impurity standards as vital components of medicine quality assurance.

The conference was inaugurated by Prof. Shailendra Saraf of NIPER Hyderabad, who praised the collaboration between academic institutions and regulatory bodies like IPC to enhance pharmaceutical quality initiatives. Dr. V. Kalaiselvan, IPC's Secretary-cum-Scientific Director, highlighted the crucial role of impurity profiling and pharmacopoeial standards in mitigating adverse pharmaceutical effects. Renowned experts joined discussions on harmonized standards, regulatory control, and advancements related to the upcoming Indian Pharmacopoeia 2026.

(With inputs from agencies.)